BACKGROUND: Colorectal cancer (CRC) is a malignant tumor of the digestive system with high incidence rate and mortality. Tanshinone IIA (Tan IIA) plays an anti-cancer role in a variety of cancer cells. Here, we aimed to elucidate the therapeutic effects and potential mechanism of Tan IIA in CRC. METHODS: OUMS23 cells were treated with 0, 5, 10, or 20 μM Tan IIA, and CRC mice were exposed to 20 μM Tan IIAâ+âSLC7A11 plasmid. Edu and flow cytometry analyses were performed to assay cell proliferation and apoptosis, respectively. An Iron Assay Kit was used for determining total iron and Fe(2+) levels in intracellular and tumor tissues. Lipid reactive oxygen species (ROS) production was evaluated by flow cytometry. SLC7A11 expression was analyzed by reverse transcription-quantitative PCR (RT-qPCR), Western blot assay, and immunohistochemistry (IHC). The activation status of the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (TOR) pathway was determined by Western blotting. RESULTS: Tan IIA suppressed CRC proliferation in a dose-dependent manner. Moreover, Tan IIA inhibited SLC7A11 expression in OUMS23 cells and tumor tissues. Functional assays showed that Tan IIA induces CRC apoptosis, ferroptosis, and ROS release in intracellular and tumor tissues, while SLC7A11 plasmid transfection reverses these effects. Furthermore, SLC7A11 plasmid reversed the effects of Tan IIA on tumor volume and weight in CRC subcutaneous tumors. Further experiments revealed that SLC7A11 plasmid abolished the effects of Tan IIA on the PI3K/AKT/mTOR pathway, as confirmed by increased phospho (p)-AKT and p-mTOR expression, as well as increased p-AKT/AKT and p-mTOR/ mTOR ratios. CONCLUSION: Tan IIA induces ferroptosis in CRC by suppressing SLC7A11 expression through the PI3K/AKT/mTOR pathway. Therefore, Tan IIA may be an effective therapeutic agent in the treatment of CRC.
Tanshinone IIA induces ferroptosis in colorectal cancer cells through the suppression of SLC7A11 expression via the PI3K/AKT/mTOR pathway.
丹参酮 IIA 通过 PI3K/AKT/mTOR 通路抑制 SLC7A11 表达,从而诱导结直肠癌细胞发生铁死亡
阅读:5
作者:Ge Tingrui, Li Huazhuan, Xiang Ping, Yang Dong, Zhou Jingyi, Zhang Yonggang
| 期刊: | European Journal of Medical Research | 影响因子: | 3.400 |
| 时间: | 2025 | 起止号: | 2025 Jul 5; 30(1):576 |
| doi: | 10.1186/s40001-025-02842-7 | 研究方向: | 细胞生物学 |
| 疾病类型: | 肠癌 | 信号通路: | PI3K/Akt、mTOR |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
